These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 22717869)
1. Serum CRP protein as a differential marker in cancer. Juan H; Qijun W; Junlan L Cell Biochem Biophys; 2012 Nov; 64(2):89-93. PubMed ID: 22717869 [TBL] [Abstract][Full Text] [Related]
2. Osteopontin as a marker of weight loss in lung cancer. Karadag F; Gulen ST; Karul AB; Kilicarslan N; Ceylan E; Kuman NK; Cildag O Scand J Clin Lab Invest; 2011 Dec; 71(8):690-4. PubMed ID: 22017168 [TBL] [Abstract][Full Text] [Related]
3. Resistin - concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Stejskal D; Adamovská S; Bartek J; Juráková R; Prosková J Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2003 Nov; 147(1):63-9. PubMed ID: 15034607 [TBL] [Abstract][Full Text] [Related]
4. C-reactive protein concentrations and subsequent ovarian cancer risk. McSorley MA; Alberg AJ; Allen DS; Allen NE; Brinton LA; Dorgan JF; Pollak M; Tao Y; Helzlsouer KJ Obstet Gynecol; 2007 Apr; 109(4):933-41. PubMed ID: 17400857 [TBL] [Abstract][Full Text] [Related]
5. Serum C-reactive protein in the differential diagnosis of ovarian masses. Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929 [TBL] [Abstract][Full Text] [Related]
6. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Allin KH; Nordestgaard BG Crit Rev Clin Lab Sci; 2011; 48(4):155-70. PubMed ID: 22035340 [TBL] [Abstract][Full Text] [Related]
7. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Trichopoulos D; Psaltopoulou T; Orfanos P; Trichopoulou A; Boffetta P Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):381-4. PubMed ID: 16492932 [TBL] [Abstract][Full Text] [Related]
8. Significance of albumin and C-reactive protein variations in 300 end stage renal disease patients in Tehran University of Medical Sciences Hospitals during year 2010. Dashti N; Einollahi N; Nabatchian F; Moradi Sarabi M; Zarebavani M Acta Med Iran; 2012; 50(3):197-202. PubMed ID: 22418989 [TBL] [Abstract][Full Text] [Related]
9. Adipocyte fatty acid binding protein and C-reactive protein levels as indicators of insulin resistance development. Horakova D; Pastucha D; Stejskal D; Kollarova H; Azeem K; Janout V Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):355-9. PubMed ID: 22336648 [TBL] [Abstract][Full Text] [Related]
10. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Karadag F; Kirdar S; Karul AB; Ceylan E Eur J Intern Med; 2008 Mar; 19(2):104-8. PubMed ID: 18249305 [TBL] [Abstract][Full Text] [Related]
11. High-sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthma. Zietkowski Z; Tomasiak-Lozowska MM; Skiepko R; Mroczko B; Szmitkowski M; Bodzenta-Lukaszyk A Respir Med; 2009 Mar; 103(3):379-85. PubMed ID: 19010654 [TBL] [Abstract][Full Text] [Related]
12. C-reactive protein and erythrocyte sedimentation rate discordance: frequency and causes in adults. Feldman M; Aziz B; Kang GN; Opondo MA; Belz RK; Sellers C Transl Res; 2013 Jan; 161(1):37-43. PubMed ID: 22921838 [TBL] [Abstract][Full Text] [Related]
13. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related]
14. C-reactive protein and risk of breast cancer. Zhang SM; Lin J; Cook NR; Lee IM; Manson JE; Buring JE; Ridker PM J Natl Cancer Inst; 2007 Jun; 99(11):890-4. PubMed ID: 17551149 [TBL] [Abstract][Full Text] [Related]
15. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. Siemes C; Visser LE; Coebergh JW; Splinter TA; Witteman JC; Uitterlinden AG; Hofman A; Pols HA; Stricker BH J Clin Oncol; 2006 Nov; 24(33):5216-22. PubMed ID: 17114654 [TBL] [Abstract][Full Text] [Related]
16. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Wieland A; Kerbl R; Berghold A; Schwinger W; Mann G; Urban C Med Pediatr Oncol; 2003 Jul; 41(1):21-5. PubMed ID: 12764738 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of a sensitive immunoluminometric assay for the determination of C-reactive protein (CRP) in serum and plasma and the establishment of reference ranges for different groups of subjects. Wood WG; Lüdemann J; Mitusch R; Heinrich J; Maass R; Frick U Clin Lab; 2000; 46(3-4):131-40. PubMed ID: 10791120 [TBL] [Abstract][Full Text] [Related]
18. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108 [TBL] [Abstract][Full Text] [Related]
19. [Measurement of C-reactive protein gives valuable information in patients with all types of inflammation]. Husebekk A Tidsskr Nor Laegeforen; 1991 Apr; 111(9):1127-9. PubMed ID: 2024262 [TBL] [Abstract][Full Text] [Related]
20. C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease. Kazemi-Bajestani SM; Ghayour-Mobarhan M; Ebrahimi M; Moohebati M; Esmaeili HA; Ferns GA Clin Lab; 2007; 53(1-2):49-56. PubMed ID: 17323825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]